Bone Therapeutics SA logo

BOTHE - Bone Therapeutics SA Share Price

€2.8 -0.0  -1.4%

Last Trade - 1:02pm

Sector
Healthcare
Size
Micro Cap
Market Cap £40.3m
Enterprise Value £50.5m
Revenue £n/a
Position in Universe 629th / 847
Bullish
Bearish
Unlock BOTHE Revenue
Momentum
Relative Strength (%)
1m -2.68%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -23.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.041 1.00 0.000 1.75 6.31
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, BoneTherapeutics SA revenues was not reported. Net lossapplicable to common stockholders increased 78% to EUR9.8M.Higher net loss reflects Lab fees & other operatingexpenses increase from EUR2.1M to EUR5.9M (expense), OtherOperating Income decrease of 38% to EUR1M (income), OtherG&A Expenses increase of 15% to EUR828K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BOTHE Revenue Unlock BOTHE Revenue

Net Income

BOTHE Net Income Unlock BOTHE Revenue

Normalised EPS

BOTHE Normalised EPS Unlock BOTHE Revenue

PE Ratio Range

BOTHE PE Ratio Range Unlock BOTHE Revenue

Dividend Yield Range

BOTHE Dividend Yield Range Unlock BOTHE Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BOTHE EPS Forecasts Unlock BOTHE Revenue
Profile Summary

Bone Therapeutics SA is a Belgium-based company developing cell therapy products. The Company develops cell therapy products for the treatment and regeneration of bone tissue and bone reconstruction applications, osteonecrosis, ununited fractures, and maxillo-facial reconstruction. It is engaged in research, enable adult stem cell isolation, expansion, and osteogenic differentiation.The Company’s therapeutic area focus is bone diseases, with extensions to joint, mainly osteoarthritis and disc degeneration.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated June 22, 2006
Public Since February 6, 2015
No. of Shareholders: n/a
No. of Employees: 70
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Euronext - Brussels
Shares in Issue 16,478,168
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BOTHE Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BOTHE
Upcoming Events for BOTHE
Frequently Asked Questions for Bone Therapeutics SA
What is the Bone Therapeutics SA share price?

As of 1:02pm, shares in Bone Therapeutics SA are trading at €2.8, giving the company a market capitalisation of £40.3m. This share price information is delayed by 15 minutes.

How has the Bone Therapeutics SA share price performed this year?

Shares in Bone Therapeutics SA are currently trading at €2.8 and the price has moved by -21% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bone Therapeutics SA price has moved by -28.67% over the past year.

What are the analyst and broker recommendations for Bone Therapeutics SA?

Of the analysts with advisory recommendations for Bone Therapeutics SA, there are there are currently 1 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Bone Therapeutics SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Bone Therapeutics SA next release its financial results?

Bone Therapeutics SA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Bone Therapeutics SA dividend yield?

Bone Therapeutics SA does not currently pay a dividend.

Does Bone Therapeutics SA pay a dividend?

Bone Therapeutics SA does not currently pay a dividend.

When does Bone Therapeutics SA next pay dividends?

Bone Therapeutics SA does not currently pay a dividend.

How do I buy Bone Therapeutics SA shares?

To buy shares in Bone Therapeutics SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Bone Therapeutics SA?

Shares in Bone Therapeutics SA are currently trading at €2.8, giving the company a market capitalisation of £40.3m.

Where are Bone Therapeutics SA shares listed? Where are Bone Therapeutics SA shares listed?

Here are the trading details for Bone Therapeutics SA:

Country of listing: Belgium
Exchange: BRU
Ticker Symbol: BOTHE
What kind of share is Bone Therapeutics SA?

Based on an overall assessment of its quality, value and momentum, Bone Therapeutics SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Bone Therapeutics SA share price forecast 2021?

Shares in Bone Therapeutics SA are currently priced at €2.8. At that level they are trading at 66.55% discount to the analyst consensus target price of 0.00.

Analysts covering Bone Therapeutics SA currently have a consensus Earnings Per Share (EPS) forecast of -0.66 for the next financial year.

How can I tell whether the Bone Therapeutics SA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bone Therapeutics SA. Over the past six months, the relative strength of its shares against the market has been 9.55%. At the current price of €2.8, shares in Bone Therapeutics SA are trading at 6.76% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Bone Therapeutics SA PE Ratio?

We were not able to find PE ratio data for Bone Therapeutics SA.

Who are the key directors of Bone Therapeutics SA?

Bone Therapeutics SA's management team is headed by:

Olivier Godeaux - OTH
Benoit Moreaux - CTO
Jean Stephenne - CHM
Gloria Matthews - IND
Miguel Forte - CEO
Claudia D'Augusta - IND
Damian Marron - IND
Jean-Paul Prieels - IND
Jean-Luc Vandebroek - CFO
Stefanos Theoharis - OTH
Who are the major shareholders of Bone Therapeutics SA?

Here are the top five shareholders of Bone Therapeutics SA based on the size of their shareholding:

CPH Banque Corporation
Percentage owned: 8.09% (1.33m shares)
Société Régionale d'Investissement de Wallonie S.A. (SRIW) Corporation
Percentage owned: 6.81% (1.12m shares)
SFPI-FPIM Investment Advisor
Percentage owned: 2.53% (416k shares)
La Banque Postale Asset Management Investment Advisor
Percentage owned: 0.32% (52.6k shares)
Tocqueville Silver Age ISR Mutual Fund
Percentage owned: 0.32% (52.6k shares)
Similar to BOTHE
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.